Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn’s disease

Table 2 Clinical and demographic patient characteristics n (%)

Variables	Total	Anti-TNF treatment		P value
		Non-responders	Ever responders
Total	121 (100)	21 (17)	100 (83)	NA
Patient demographics
Gender
Female	71 (59)	15 (71)	56 (56)	NS
Male	50 (41)	6 (29)	44 (44)
Race
Caucasian	112 (93)	21 (100)	91 (91)	NS
African American	9 (7)	0 (0.0)	9 (9)
Socioeconomic status1
1st Quartile	24 (20)	4 (19)	20 (20)	NS
2nd Quartile	40 (33)	6 (29)	34 (34)
3rd Quartile	29 (24)	3 (14)	26 (26)
4th Quartile	28 (23)	8 (38)	20 (20)
Montreal classification
Age of onset (A)
A1 - below 16 years old	14 (12)	1 (5)	13 (13)	NS
A2 - between 17 and 40 years old	90 (74)	17 (81)	73 (73)
A3 - above 40 years old	17 (14)	3 (14)	14 (14)
Location (L)
L1 - ileal	15 (12)	1 (5)	14 (14)	NS
L2 - colonic	32 (26)	5 (24)	27 (27)
L3 - ileocolonic	74 (61)	15 (71)	59 (59)
Location (L4) upper
No upper GI disease	118 (98)	21 (100)	97 (97)	NS
L4 - upper GI disease	3 (2)	0 (0)	3 (3)
Behavior (B)
B1 - non-stricturing, non-penetrating	36 (30)	4 (19)	32 (32)	0.1
B2 - stricturing	45 (37)	12 (57)	33 (33)
B3 - penetrating	40 (33)	5 (24)	35 (35)
Behavior (p) perianal disease
No perianal disease	84 (69)	18 (86)	66 (66)	0.08
p - perianal disease present	37 (31)	3 (14)	34 (34)
Anti-TNF treatment type
Drugs received
Infliximab	46 (38)	10 (48)	36 (36)	NS
Adalimumab	45 (38)	5 (24)	40 (40)
Infliximab and Adalimumab2	29 (24)	6 (29)	23 (23)
Certolizumab pegol	5	0	5

¹Calculated according to the national percentile of median household income;

²Received sequentially. TNF: Tumor necrosis factor.